Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
Eileen Dareng(University of Cambridge), Aleksandra Gentry‐Maharaj(UCL Australia), Ralf Bützow(Helsinki University Hospital), Linda S. Cook, Robbin Nameki(Cedars-Sinai Medical Center), Jonathan P. Tyrer(University of Cambridge), Brian Davis(Cedars-Sinai Medical Center), Marcus Q. Bernardini(University Health Network), Alberto Luiz P. Reyes(Cedars-Sinai Medical Center), Natalia Bogdanova(Medizinische Hochschule Hannover), Simon G. Coetzee(University of Southern California), Peter A. Fasching(Universitätsklinikum Erlangen), Line Bjørge(Haukeland University Hospital), Ji-Heui Seo(Dana-Farber Cancer Institute), Jenny Chang‐Claude(Universität Hamburg), Anna DeFazio(The University of Sydney), Thilo Dörk(Hannover Re (Germany)), Gabrielle Ene(University Health Network), James M. Flanagan(QIMR Berghofer Medical Research Institute), Joe Dennis(University of Cambridge), Rikki Cannioto(Roswell Park Comprehensive Cancer Center), Kelly L. Bolton(Washington University in St. Louis), Ian Campbell(The University of Sydney), Gerasimos Aravantinos(Hospital Agioi Anargyroi), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), Matthias W. Beckmann(Universitätsklinikum Erlangen), Andreas du Bois(Kliniken Essen-Mitte), Will Rosenow(University of Virginia), Hui Cai(Vanderbilt University Medical Center), Agnieszka Budziłowska(The Maria Sklodowska-Curie National Research Institute of Oncology), James D. Brenton(Cambridge University Hospitals NHS Foundation Trust), Javier Benı́tez(Spanish National Cancer Research Centre), Renée T. Fortner(Norwegian Institute of Public Health), Amanda Black(St. Elizabeth's Hospital), Yoke-Eng Chiew(The University of Sydney), Felipe Segato Dezem(St. Jude Children's Research Hospital), Jennifer A. Doherty(Cancer Prevention Institute of California), Hoda Anton‐Culver(University of California, Irvine), Matthias Dürst(Jena University Hospital), Pei-Chen Peng(Cedars-Sinai Medical Center), Laura E. Beane Freeman(National Cancer Institute), Stephen J. Chanock(National Cancer Institute), Kexin Chen(Harbin University of Science and Technology), Stephanie Chen(Rutgers, The State University of New Jersey), Alicia Beeghly‐Fadiel(University of Helsinki), Natalia Antonenkova(N.N. Alexandrov National Cancer Centre), Katja K.H. Aben(Radboud University Nijmegen), Florentia Fostira(National Centre of Scientific Research "Demokritos"), Elisa V. Bandera(Rutgers, The State University of New Jersey)
Cited by 25
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
|Nature Genetics|2010|3k